Google
ROIV — ROIVANT SCIENCES LTD (Healthcare >> Biotechnology)
ROIV FAQ
What is ROIV's P/E ratio?
ROIVANT SCIENCES LTD (ROIV) currently trades at a P/E ratio of 79.17.
What is ROIV's ROE?
ROIVANT SCIENCES LTD reports a Return on Equity (ROE) of -6.62%.
What is ROIV's dividend yield?
ROIVANT SCIENCES LTD offers a dividend yield of 0.00%.
What is ROIV's Deepscope Quality Score?
Deepscope rates ROIV's overall financial quality at 23 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy ROIV?
Deepscope's AI Timing Score for ROIV is 67 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does ROIV belong to?
ROIVANT SCIENCES LTD is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange.
|
USD 29.53
Price
0.83
(2.89%)
Day Change
|
|
|---|
ROIV, the overall quality is not good ( Quality = 23) and the timing to buy is ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
P/E ratio is relatively high
ROE is relatively low.
ROA is relatively low.
Acceleration of ROE growth rate is below our criteria.
Historical ROE is relatively low
Negative growth of ROE in the last year.
ROA is too relatively low compare to ROE
Acceleration of ROA growth rate is below our criteria.
Growth of ROA was below our criteria in the last year.
Net profit margin is relatively low.
Acceleration of net profit margin growth rate is below our criteria
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
In details, quality factors are not good , financial health is not good , and ability to make profit is ok , ...
| Quality Factors |
|
39% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 92 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 29.53 |
| PBV / Sector |
4.53 / 4.58
|
| Earning Per Share | -0.43 |
| PE / Sector |
79.17 / 17.10
|
| PEG or PE/Growth / Sector |
-0.28 / 0.52
|
| Average 1M Daily Value |
187.64 M
GREAT
|
| Average 1W Daily Value |
138.02 M
GREAT
|
| Timing Factors |
|
42% |
| Financial Health |
|
41% |
| Ability to Make Profit |
|
60% |
| Return to Investors |
|
4% |
| Registration Details |
| Analyze Date | 2026-06-05 09:11:59 |
| Symbol | ROIV |
| Name | ROIVANT SCIENCES LTD |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 719.27 M |
| Par Value | N/A |
| Calculated From | YearEnd |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 23,986.84 / 8,655.90 |
| News, Concensus, ... |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 50 Broadway, London, United Kingdom, SW1H 0DB
Phone: 44 20 7400 3347
Website: https://roivant.com
Employees: 721
Sector: Healthcare >> Biotechnology
Description: Roivant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines and technologies. Its clinical product candidates include IMVT-1402, a fully human monoclonal antibody targeting FcRn in development across several IgG-mediated autoimmune indications; mosliciguat, an inhaled sGC activator in development for pulmonary hypertension associated with interstitial lung disease; neonatal fragment crystallizable receptor for the treatment of graves' disease, difficult-to-treat rheumatoid arthritis, sjögren's disease, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and cutaneous lupus erythematosus indications; batoclimab, a fully human monoclonal antibody for the treatment of thyroid eye disease; and brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis, non-infectious uveitis, cutaneous sarcoidosis, and other immune-mediated diseases. The company's lead program consists of mosliciguat, an inhaled sGC activator for the treatment of pulmonary hypertension associated with interstitial lung disease and other cardiopulmonary diseases. In addition, the company offers delivery platforms comprising a lipid nanoparticle (LNP) platform and a ligand conjugate platform. Roivant Sciences Ltd. was founded in 2014 and is based in London, United Kingdom.
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
